A randomised, double-blind, parallel group study evaluating the efficacy and safety of co administration of triple combinations of olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide compared with the corresponding olmesartan- amlodipine combination in subjects with hypertension

Registry ID

EUCTR2008-003534-25

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

DAIICHI SANKYO EUROPE GmbH

Start date

2009-05-13

Completion date

2011-01-04

Last update

2026-08-16

Conditions

• Essential hypertension
• Essential hypertension Hipertensión esencial

Summary

The main objective of this study is to demonstrate that OM/AML/HCTZ triple combinations are more efficacious in lowering SeDBP than corresponding dual combinations of OM/AML after 10 weeks of double blind treatment.

Locations

• , , Italy
• , , Netherlands
• , , Slovakia
• , , Belgium
• , , Bulgarian Drug Agency
• , , Denmark
• , , Latvia
• , , Spain
• , , Czechia
• , , Germany

View on source registry